Physician profile
James A Wright
NPI 1245234053
$17,881.86
in general payments reported to CMS, 2019-2025
54 companies · $2,085 in 2025
The $2,085 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $997 · 2021: $2,751 · 2022: $3,685 · 2023: $3,642 · 2024: $2,937 · 2025: $2,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,658 · Education: $5.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,658.37 |
| Education | $5.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,491.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,617.20 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,492.55 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $1,412.00 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,190.71 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $1,002.52 | 2019-2025 | Entresto |
| Janssen Pharmaceuticals, INC | $934.98 | 2019-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $796.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $669.74 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $657.52 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $542.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $497.23 | 2023-2024 | Synchromedii, Minimed 780g, Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $441.13 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $409.20 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $308.10 | 2022-2025 | Caplyta |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.